Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...

H.C. Wainwright analyst Ed Arce keeps a Neutral rating on Durect (DRRX) without a price target after the company announced that data from the ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in ...

Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Immunocore in a research report issued to ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.11% ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the ...

H.C. Wainwright analyst Arthur He initiated coverage of Nektar (NKTR) with a Buy rating and $6.50 price target Nektar is a clinical-stage biopharmaceutical company focused on developing innovative ...